The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

Adoptive cell therapy based on ex-vivo expanded tumor-infiltrating lymphocytes (TILs) has historically been most effective in ...

CHICAGO – A CRISPR-Cas9-based investigational therapy was ... was delivered to patients (n=36) with ATTR-CM, explained Marianna Fontana, MD, PhD, of University College London, and the mean ...

In a new study published in Nature titled, “Custom CRISPR-Cas9 PAM variants via scalable engineering and machine learning,” researchers from Massachusetts General Hospital (MGH) and Harvard ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes ... might be ...

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

The CRISPR/Cas9 gene-editing technique has shown promise in fighting advanced colorectal cancer, according to results of the ...

"Our study is a first step in dramatically expanding our repertoire of effective and safe CRISPR-Cas9 enzymes. In our manuscript, we demonstrate the utility of these PAMmla-predicted enzymes to ...

A first-in-human clinical trial tests a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.